List view / Grid view
European approval of Sanofi and Regeneron’s monoclonal antibody provides eligible…
European approval of Sanofi and Regeneron’s monoclonal antibody provides eligible urticaria patients with a new first-line targeted treatment option.
The US approval could improve outcomes for eligible patients with…
The US approval could improve outcomes for eligible patients with previously limited options for managing the inflammatory skin condition.
Tremfya inhibited radiographic progression and provided durable improvements in symptoms…
Tremfya inhibited radiographic progression and provided durable improvements in symptoms of axial involvement in psoriatic arthritis patients.
Over 50 percent of psoriatic arthritis patients treated with Tremfya®…
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
The joint and skin response rates of adults with active…
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya® (guselkumab) were maintained over two years.
